Observational studyBMJ open2026
Anxiety-depression interaction and somatic symptoms in functional gastrointestinal disorders: a retrospective cross-sectional study from gastroenterology outpatient clinics.
Observational study in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to explore the psychosomatic state of patients with functional gastrointestinal disorders (FGIDs), with the hypothesis that depression and anxiety are closely associated with somatic symptoms in patients with FGIDs.
designRetrospective cross-sectional study.
settingThe study was conducted in gastroenterology outpatient clinics.
participantsThe analysis included 655 patients with FGIDs treated between March 2021 and December 2024.
interventionsThere were no interventions in this observational study. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome measure was the somatisation subscale score of the Symptom Checklist-90 (SCL-90-SOM). Secondary outcome measures included scores of the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale (SDS). Heart rate variability (HRV) was also measured.
resultsPatients with FGIDs demonstrated relatively high SAS and SDS scores. Multivariable linear regression showed that female gender and higher SAS score were associated with higher SCL-90-SOM scores after adjustment for available covariates. SDS score showed a negative coefficient after adjustment for SAS, which may reflect adjustment-related suppression or symptom-scale overlap rather than a protective effect of depressive symptoms. A statistically significant interaction between SAS and SDS on somatic symptoms was observed using standardised variables (B=0.042, 95% CI 0.018 to 0.067,
conclusionsAmong patients with FGIDs in this single-centre outpatient sample, anxiety symptoms were strongly associated with higher somatic symptom burden. Depressive symptoms modified the association between anxiety and somatic symptoms in the interaction model. However, interpretation is limited by the cross-sectional design, possible symptom-scale overlap and residual confounding. These findings support further prospective studies and suggest that assessment of co-occurring anxiety and depressive symptoms may be clinically relevant in FGID care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.